This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zealand Pharma A/S Stock (NASDAQ:ZEAL) 30 days 90 days 365 days Advanced Chart Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$17.59▼$17.5950-Day Range$16.54▼$19.2052-Week Range$9.93▼$32.94VolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More… Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZEAL Stock News HeadlinesTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMay 27 at 4:00 PM | globenewswire.comEuropean stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%May 26, 2025 | msn.comBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.May 30, 2025 | Golden Portfolio (Ad)Lilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comLilly’s former small molecule head makes the leap to a rising biotech in obesityMay 22, 2025 | finance.yahoo.comZealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development OfficerMay 19, 2025 | globenewswire.comZealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is PriceyMay 16, 2025 | seekingalpha.comZealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025May 12, 2025 | globenewswire.comSee More Headlines ZEAL Stock Analysis - Frequently Asked Questions How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) EPS for the quarter, beating analysts' consensus estimates of ($6.31) by $1.70. The company earned $16.87 million during the quarter, compared to analyst estimates of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%. When did Zealand Pharma A/S IPO? Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/10/2021Today5/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.99 million Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales17.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book5.20Miscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ZEAL) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored"I'm risking my reputation on this"The Secret Behind 90% of Crypto’s Biggest Gains There are plenty solution-driven opportunities emerging rig...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.